

## Supporting information

### **Growth Factor Mimic 3,4-dihydroxyphenylalanine encoded bioartificial extracellular matrix like protein promotes wound closure and angiogenesis**

Ilamaran Meganathan<sup>a</sup>, Ashokraj Sundrapandian<sup>a</sup>, Aarthi M<sup>a</sup>, Ganesh Shanmugam<sup>b</sup>, Ganesan Ponesakki<sup>a</sup>, Kamini Numbi Ramudu<sup>a</sup> and Ayyadurai Niraikulam<sup>a\*</sup>

<sup>a</sup>Division of Biochemistry and Biotechnology, Council of Scientific and Industrial Research (CSIR) - CLRI, Chennai, India.

<sup>b</sup>Division of Organic and Bioorganic Chemistry, Council of Scientific and Industrial Research (CSIR) - CLRI, Chennai, India.

Corresponding author

Dr. N. Ayyadurai

Division of Biochemistry and Biotechnology,

Council of Scientific and Industrial Research (CSIR) - CLRI, Chennai, India.

E-mail: ayyadurai@clri.res.in, ayyadurai@gmail.com

## **Materials**

Expression host *Escherichia coli* tyrosine auxotroph (*E. coli*) *JW2581* was received from Coli Genetic stock center (CT, USA). The CLP synthetic gene in pMK-RQ vector was purchased from Invitrogen (CA, USA) and pQE80-L vector purchased from Qiagen (Valencia, USA). All restriction enzymes and T4 DNA ligase were purchased from New England Biolabs (Ipswich, US). Natural amino acids, M9 salts, 3, 4- dihydroxy-L-phenylalanine (DOPA) and RNA isolation reagent TRI reagent<sup>®</sup> were purchased from Sigma-Aldrich (Bangalore, India). Isopropyl  $\beta$ - d-1-thiogalactopyranoside (IPTG), ampicillin, Luria–Bertani (LB) broth and imidazole were purchased from Himedia (Mumbai, India). Protein purification His-trap HP column was purchased from GE healthcare (Bangalore, India).

## **Construction of plasmids and strains**

The CLP gene amplified from CLP-pMK-RQ vector with gene specific primers was cloned into pQE80L vector using *BamHI* and *Hind III* restriction enzymes and T4 DNA ligase as per the procedure described by Sambrook and Russel (Sambrook et al., 1989). Then, the ligated CLP-pQE80L vector was transformed into *E.coli* tyrosine auxotroph (*JW2581*). Expression of CLP protein in tyrosine auxotroph was carried out by growing the bacterial culture in LB broth containing ampicillin (100  $\mu$ g/mL). After the growth reaches 0.6 OD<sub>600</sub>, protein expression was induced with 1mM IPTG and incubated overnight at 37 °C. The expression of the CLP protein was confirmed by running the total cell fraction on a 12% SDS-PAGE.




**Figure S1.** A) Confirmation of CLP gene inserion in pQE80L vector by double digestion of pQE80l+CLP vector by *BamHI* and *HindIII* restriction enzymes, B) CLP and CLPDOPA expression analysis of whole cell lysate lane 1) CLPDOPA, 2) CLP, 3) whole cell lysate without IPTG induction, 4) protein marker.

**Confirmation and quantification of orthogonal residue specific DOPA incorporation in CLP**


## Nitroblue tetrazolium (NBT) staining assay

**A**



**Figure S2.** SDS-PAGE resolved Lane 1) CLPDOPA and 2) CLP were trans-blotted into nitrocellulose membrane and the incorporation of L-DOPA in CLPDOPA protein was confirmed by Nitroblue tetrazolium (NBT) staining method.

## Matrix Assisted Laser Desorption Ionization-Time of Flight (MALDI-TOF) analysis




**Figure S3.** Total mass spectrum of in gel digested CLP and CLPDOPA proteins analyzed by MALDI-TOF .

Table 1: MALDI Mass analysis

| Protein | Total number of tyrosine present | Molecular mass of Maldi analysis | % of DOPA incorporation |
|---------|----------------------------------|----------------------------------|-------------------------|
| CLP     | 3                                | 34615                            | -                       |
| CLPDOPA | -                                | 34661                            | 90%                     |

## Amino acid analysis




**Figure S4.** Quantification of orthogonal translational incorporation of L-DOPA into the CLPDOPA protein by HPLC based amino acid analysis.

**Table 2.** Amino acid analysis quantification of DOPA present in CLPDOPA protein.


| Protein  | Area of tyrosine peak | % of tyrosine present | % of DOPA incorporation | Number of tyrosine present |
|----------|-----------------------|-----------------------|-------------------------|----------------------------|
| CLP      | 57495387              | 100                   | -                       | 3                          |
| CLP DOPA | 5878331               | 10                    | 90                      | -                          |

## Purification of CLP and CLPDOPA proteins




**Figure S5.** Affinity chromatography purified heat denatured Lane 1) CLP, 2) Marker, 3) CLPDOPA proteins were resolved in SDS-PAGE.

## CD secondary structural analysis of CLPDOPA protein




**Figure S6.** CD spectrometric analysis of triple helical CLPDOPA and CLP.



**Figure S7.** CD spectrometric analysis of renatured A) CLPDOPA and B) CLP. C) CD analysis of refolding of CLP and CLPDOPA at 220nm.




## Temperature stability analysis by Fluorescence spectrometry




**Figure S8.** Temperature dependent structural unfolding of CLPDOPA and CLP proteins measured by NanoDSF using intrinsic tryptophan fluorescence emission intensity measured at 350 nm/330 nm.

## Self-assembly and fibrillation of CLP and RTT proteins



**Figure S9.** Turbidometric analysis of A) RTT, B) CLP fibrillation kinetics at physiological pH was monitored at 313 nm.



**Figure S10.** A) 3T3/NIH cell proliferation (MTT assay) at 48 h. B & C) EAhy926 human endothelial cell proliferation (MTT assay) of CLP, CLPDOPA, RTT proteins, D & E) Live cell image monitored EAhy926 human endothelial cell growth rate and speed of wound closure in the presence of 10  $\mu\text{g}/\text{mL}$  of CLP and CLPDOPA protein in serum free medium